Alcoholic Hepatitis Clinical Trial
Official title:
An Open-Label, Cohort Dose Escalation Study to Assess the Safety and Efficacy of F-652 in Patients With Alcoholic Hepatitis
Alcoholic hepatitis is a syndrome of progressive inflammatory liver injury associated with
long-term heavy intake of ethanol. The pathogenesis is not completely understood. Patients
who are severely affected present with subacute onset of fever, hepatomegaly, leukocytosis,
marked impairment of liver function (e.g., jaundice, coagulopathy), and manifestations of
portal hypertension (e.g., ascites, hepatic encephalopathy, variceal hemorrhage). However,
milder forms of alcoholic hepatitis often do not cause any symptoms.
Alcoholic hepatitis usually persists and progresses to cirrhosis if heavy alcohol use
continues. If alcohol use ceases, alcoholic hepatitis resolves slowly over weeks to months,
sometimes without permanent sequelae but often with residual cirrhosis.
F-652 is a recombinant fusion protein containing human interleukin 22 (IL-22) and human
Immunoglobulin G2 (IgG2)-Fc produced in CHO cells in serum-free culture. F-652 under
development is intended to treat patients with graft vs host disease (GvHD) after bone marrow
transplantation, and acute alcoholic hepatitis (AAH), a severe form of alcoholic liver
disease (ALD). Both GvHD and AAH are diseases with unmet medical need. The current
investigational new drug (IND) application is to conduct a phase Ia clinical study in GvHD
patients to evaluate the safety and pharmacokinetic profile, and biomarkers of F-652
treatment by intravenous infusion (IV).
IL-22 is a member of the IL-10 family of cytokines which control bacterial infection,
homeostasis, and tissue repair. IL-22 may be used to treat patients with ALD because of its
antioxidant, anti-apoptotic, anti-steatotic, anti-microbial, and proliferative effect that
have been demonstrated in various experimental systems.
IL-22 is a member of the IL-10 family of cytokines which control bacterial infection,
homeostasis, and tissue repair. IL-22 may be used to treat patients with ALD because of its
antioxidant, anti-apoptotic, anti-steatotic, anti-microbial, and proliferative effect that
have been demonstrated in various experimental systems.
The sponsor has developed F-652, a recombinant human IL-22 IgG2 Fc fusion protein produced in
serum-free culture of Chinese Hamster Ovary (CHO) cells. F-652 is able to protect tissue from
damage and enhance tissue repair during the inflammation process and infection by activation
of STAT3 mediated by the interleukin-22 receptor subunit 1 (IL-22R1) expressed on epithelial
cells such as hepatocytes.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04066179 -
Efficacy of Monotherapy vs Combination Therapy of Corticosteroids With GCSF in Severe Alcoholic Hepatitis Patients.
|
N/A | |
| Completed |
NCT03732586 -
Effect of Omega 5 Fatty Acid as an Adyuvant Treatment to Prednisone in Patients With Severe Alcoholic Hepatitis
|
N/A | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Completed |
NCT00962442 -
N-Acetylcysteine in Severe Acute Alcoholic Hepatitis
|
Phase 3 | |
| Not yet recruiting |
NCT06307522 -
MRG-001 in Patients With Alcoholic Hepatitis
|
Phase 2 | |
| Recruiting |
NCT05018481 -
HA35 Moderate Alcoholic Hepatitis (AH) Study
|
Early Phase 1 | |
| Completed |
NCT04544020 -
Changes in gUt micRobiota After Enteral Feeding (in Alcoholic Hepatitis)
|
||
| Recruiting |
NCT04088370 -
Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis
|
||
| Completed |
NCT04235855 -
EUS Guided Liver Biopsy - Will it Give Better Yield, More Tissue With Less Complication?
|
N/A | |
| Active, not recruiting |
NCT02344680 -
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
|
||
| Completed |
NCT00851981 -
Randomized, Controlled Trial of S-adenosylmethionine in Alcoholic Liver Disease
|
Phase 2 | |
| Completed |
NCT04084522 -
Effect of Saturated Fat (Desi Ghee) on Gut-Liver Axis in Alcoholic Hepatitis
|
N/A | |
| Completed |
NCT05840640 -
Granulocyte Colony Stimulating Factor Four Week Plus N-Acetyl Cysteine in Severe Alcoholic Hepatitis
|
Phase 4 | |
| Recruiting |
NCT03069300 -
N-ACetylcysteine to Reduce Infection and Mortality for Alcoholic Hepatitis
|
Phase 3 | |
| Terminated |
NCT02039219 -
Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)
|
Phase 2 | |
| Completed |
NCT02019056 -
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
|
Phase 2 | |
| Completed |
NCT01245257 -
Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis
|
N/A | |
| Completed |
NCT00388323 -
Adipose Tissue Involvement in Alcohol-induced Liver Inflammation in Human
|
N/A | |
| Recruiting |
NCT03845205 -
Alcohol Treatment Outcomes Following Early vs. Standard Liver Transplant for SAH
|
N/A | |
| Recruiting |
NCT03703674 -
GCSF in Alcoholic Hepatitis
|
Phase 4 |